Pharmacology of the Phosphate Binder, Lanthanum Carbonate
Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure recei...
Saved in:
Published in | Renal failure Vol. 33; no. 2; pp. 217 - 224 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
England
Informa Healthcare
01.03.2011
Taylor & Francis |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in several experimental models. Lanthanum carbonate and aluminum hydroxide markedly increased excretion of [32P]-phosphate in feces and reduced excretion in urine in rats with normal renal function (p < 0.05), indicating good dietary phosphate-binding efficacy. In rats with chronic renal failure, lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly than calcium carbonate, which in turn was more effective than sevelamer hydrochloride. The potential to induce adverse pharmacological effects was assessed systematically in mice, rats, and dogs with normal renal function using standard in vivo models. There was no evidence of any adverse secondary pharmacological effects of lanthanum carbonate on the central nervous, cardiovascular, respiratory, or gastrointestinal systems. These studies indicate that lanthanum carbonate is the more potent of the currently available dietary phosphate binders. No adverse secondary pharmacological actions were observed in vivo in a systematic evaluation at high doses. |
---|---|
AbstractList | Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in several experimental models. Lanthanum carbonate and aluminum hydroxide markedly increased excretion of [
32
P]-phosphate in feces and reduced excretion in urine in rats with normal renal function (
p
< 0.05), indicating good dietary phosphate-binding efficacy. In rats with chronic renal failure, lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly than calcium carbonate, which in turn was more effective than sevelamer hydrochloride. The potential to induce adverse pharmacological effects was assessed systematically in mice, rats, and dogs with normal renal function using standard in vivo models. There was no evidence of any adverse secondary pharmacological effects of lanthanum carbonate on the central nervous, cardiovascular, respiratory, or gastrointestinal systems. These studies indicate that lanthanum carbonate is the more potent of the currently available dietary phosphate binders. No adverse secondary pharmacological actions were observed in vivo in a systematic evaluation at high doses. Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in several experimental models. Lanthanum carbonate and aluminum hydroxide markedly increased excretion of [ 32 P]-phosphate in feces and reduced excretion in urine in rats with normal renal function (p < 0.05), indicating good dietary phosphate-binding efficacy. In rats with chronic renal failure, lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly than calcium carbonate, which in turn was more effective than sevelamer hydrochloride. The potential to induce adverse pharmacological effects was assessed systematically in mice, rats, and dogs with normal renal function using standard in vivo models. There was no evidence of any adverse secondary pharmacological effects of lanthanum carbonate on the central nervous, cardiovascular, respiratory, or gastrointestinal systems. These studies indicate that lanthanum carbonate is the more potent of the currently available dietary phosphate binders. No adverse secondary pharmacological actions were observed in vivo in a systematic evaluation at high doses. Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in several experimental models. Lanthanum carbonate and aluminum hydroxide markedly increased excretion of [32P]-phosphate in feces and reduced excretion in urine in rats with normal renal function (p < 0.05), indicating good dietary phosphate-binding efficacy. In rats with chronic renal failure, lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly than calcium carbonate, which in turn was more effective than sevelamer hydrochloride. The potential to induce adverse pharmacological effects was assessed systematically in mice, rats, and dogs with normal renal function using standard in vivo models. There was no evidence of any adverse secondary pharmacological effects of lanthanum carbonate on the central nervous, cardiovascular, respiratory, or gastrointestinal systems. These studies indicate that lanthanum carbonate is the more potent of the currently available dietary phosphate binders. No adverse secondary pharmacological actions were observed in vivo in a systematic evaluation at high doses. Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in several experimental models. Lanthanum carbonate and aluminum hydroxide markedly increased excretion of [(32)P]-phosphate in feces and reduced excretion in urine in rats with normal renal function (p < 0.05), indicating good dietary phosphate-binding efficacy. In rats with chronic renal failure, lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly than calcium carbonate, which in turn was more effective than sevelamer hydrochloride. The potential to induce adverse pharmacological effects was assessed systematically in mice, rats, and dogs with normal renal function using standard in vivo models. There was no evidence of any adverse secondary pharmacological effects of lanthanum carbonate on the central nervous, cardiovascular, respiratory, or gastrointestinal systems. These studies indicate that lanthanum carbonate is the more potent of the currently available dietary phosphate binders. No adverse secondary pharmacological actions were observed in vivo in a systematic evaluation at high doses. |
Author | Damment, Stephen J.P. |
Author_xml | – sequence: 1 givenname: Stephen J.P. surname: Damment fullname: Damment, Stephen J.P. email: sdamment@shire.com, sdamment@shire.com organization: Shire Pharmaceuticals, Hampshire International Business Park, Chineham, Basingstoke, UK |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21332344$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kMlOwzAURS1URAf4A4TyAaR4TJxNEVRMUiW66IKd5Th2kyqxKycF9e9JFFrRTVdevHvP8ztjMLDOagBuEZwSBJMHyHkEMf6aYojQlDHMMboAI8QwCyNIkwEYdZGwywzBuK43ECLGY3wFhhgRggmlI5Asc-krqVzp1vvAmaDJdbDMXb3NZaOD58Jm2t8HC2mbXNpdFcylT51tZ9fg0siy1jd_7wSsXl9W8_dw8fn2MX9ahIpx2oSRQRxpBZVmHKKURYomVEOcoIySlBsNmcI0MimKYXtQhiNpSIzTGCmdxoRMwKzHbndppTOlbeNlKba-qKTfCycLcTqxRS7W7lsQ2AqJYQugPUB5V9dem2MXQdGZFAeTojMpepNt7e7_3mPpoK4NPPaBwhrXKvxxvsxEI_el88ZLq4q6w59dMTsh5FqWTa6k12Ljdt62Vs__8RdvApiB |
CitedBy_id | crossref_primary_10_1177_1535370218775035 crossref_primary_10_2903_j_efsa_2024_8729 crossref_primary_10_1016_j_jsps_2015_01_009 crossref_primary_10_1016_j_anndiagpath_2016_10_001 crossref_primary_10_1016_j_ccr_2019_03_003 crossref_primary_10_1111_bcp_12117 crossref_primary_10_1016_j_chemosphere_2018_12_093 crossref_primary_10_1177_1074248413486355 crossref_primary_10_1093_ckj_sfs073 crossref_primary_10_1371_journal_pone_0097859 crossref_primary_10_1248_yakushi_19_00082 crossref_primary_10_1590_2175_8239_jbn_2019_0008 crossref_primary_10_1053_j_ajkd_2020_12_012 crossref_primary_10_3109_0886022X_2014_930491 crossref_primary_10_1152_ajprenal_00137_2020 crossref_primary_10_1016_j_etap_2017_01_002 crossref_primary_10_3390_ijms232012223 crossref_primary_10_4009_jsdt_48_169 |
Cites_doi | 10.1007/BF02774187 10.5414/CNP72252 10.1097/01.ASN.0000070076.01798.0D 10.1002/jps.20956 10.3945/ajcn.2008.26665 10.1097/01.ASN.0000133022.32912.95 10.1016/S0272-6386(03)00905-3 10.1016/S0272-6386(03)00554-7 10.2215/CJN.01060308 10.1111/j.1523-1755.2005.00185.x 10.1093/ndt/gfg309 10.1093/ndt/gfh1004 10.1185/030079907X242719 10.1038/sj.ki.5001932 10.1007/3-540-29804-5 10.1097/01.ASN.0000133041.27682.A2 10.1111/j.1523-1755.2005.00171.x 10.1111/j.1525-139X.2005.18116.x 10.1093/ndt/16.9.1870 10.1007/978-1-4684-8748-0 10.5414/CNP70404 10.1016/j.toxlet.2007.04.005 10.1016/j.toxlet.2009.03.020 10.1046/j.1523-1755.1999.00240.x 10.1172/JCI113886 |
ContentType | Journal Article |
Copyright | 2011 Informa Healthcare USA, Inc. 2011 2011 The Author(s). Published by Taylor & Francis. 2011 2011 Informa Healthcare 2011 |
Copyright_xml | – notice: 2011 Informa Healthcare USA, Inc. 2011 – notice: 2011 The Author(s). Published by Taylor & Francis. 2011 – notice: 2011 Informa Healthcare 2011 |
DBID | 0YH CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM |
DOI | 10.3109/0886022X.2011.552821 |
DatabaseName | Taylor & Francis Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1525-6049 |
EndPage | 224 |
ExternalDocumentID | 10_3109_0886022X_2011_552821 21332344 552821 |
Genre | Laboratory Studies Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | --- .GJ 00X 0R~ 0YH 123 29P 36B 4.4 53G 5RE 5VS 8G5 AALIY AAPXX ABDBF ABPTK ABUWG ABWCV ACGEJ ACGFS ADBBV ADCVX ADRBQ ADXPE AENEX AEYQI AFKRA AFKVX AFLEI AJVHN AJWEG ALIIL ALMA_UNASSIGNED_HOLDINGS AOIJS ARJSQ AWYRJ AZQEC BABNJ BCNDV BENPR BLEHA BPHCQ BRMBE CAG COF CS3 CYYVM CZDIS DRXRE DWQXO DWTOO EAP EBC EBD EBS EJD EMB EMK EMOBN EPL ESX F5P GNUQQ GROUPED_DOAJ GUQSH H13 HYE HZ~ JENTW M2O M44 M4Z O9- OK1 P2P PIMPY PQEST PQQKQ PQUKI PROAC QQXMO RPM SV3 TFDNU TFL TFW TUS V1S ZGI ZXP ~1N AAORF CCPQU CGR CUY CVF ECM EIF NPM NUSFT TDBHL AAYXX CITATION 5PM |
ID | FETCH-LOGICAL-c584t-6f181ec0ce5801b56c494e0291d43b8fe05c246fb170860d26af372b71ceb733 |
IEDL.DBID | 0YH |
ISSN | 0886-022X |
IngestDate | Tue Sep 17 21:04:02 EDT 2024 Thu Sep 26 19:17:47 EDT 2024 Sat Sep 28 07:51:06 EDT 2024 Tue Jun 13 19:48:58 EDT 2023 Wed Jun 21 01:44:18 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | open-access: http://creativecommons.org/licenses/by/3.0: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. This is an open access article distributed under the Supplemental Terms and Conditions for iOpenAccess articles published in Informa Healthcare journals, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c584t-6f181ec0ce5801b56c494e0291d43b8fe05c246fb170860d26af372b71ceb733 |
OpenAccessLink | https://www.tandfonline.com/doi/abs/10.3109/0886022X.2011.552821 |
PMID | 21332344 |
PageCount | 8 |
ParticipantIDs | informaworld_taylorfrancis_310_3109_0886022X_2011_552821 crossref_primary_10_3109_0886022X_2011_552821 pubmed_primary_21332344 informahealthcare_journals_10_3109_0886022X_2011_552821 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3082170 |
PublicationCentury | 2000 |
PublicationDate | 2011-03-00 |
PublicationDateYYYYMMDD | 2011-03-01 |
PublicationDate_xml | – month: 03 year: 2011 text: 2011-03-00 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Renal failure |
PublicationTitleAlternate | Ren Fail |
PublicationYear | 2011 |
Publisher | Informa Healthcare Taylor & Francis |
Publisher_xml | – name: Informa Healthcare – name: Taylor & Francis |
References | 14520607 - Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201 19064510 - Am J Clin Nutr. 2008 Dec;88(6):1511-8 17497733 - J Pharm Sci. 2007 Oct;96(10):2818-27 15698446 - Kidney Int. 2005 Mar;67(3):1062-9 15698460 - Kidney Int. 2005 Mar;67(3):1179-87 17991307 - Curr Med Res Opin. 2007 Dec;23(12):3167-75 19825330 - Clin Nephrol. 2009 Oct;72(4):252-8 12830461 - Am J Kidney Dis. 2003 Jul;42(1):96-107 15284307 - J Am Soc Nephrol. 2004 Aug;15(8):2208-18 2744330 - Gastroenterol Jpn. 1989 Apr;24(2):135-42 18596117 - Clin J Am Soc Nephrol. 2008 Sep;3(5):1423-9 13679475 - Nephrol Dial Transplant. 2003 Oct;18(10):2014-23 9893140 - Kidney Int. 1999 Jan;55(1):299-307 17570622 - Toxicol Lett. 2007 Jun 15;171(1-2):69-77 15284308 - J Am Soc Nephrol. 2004 Aug;15(8):2219-28 19000540 - Clin Nephrol. 2008 Nov;70(5):404-10 19464128 - Toxicol Lett. 2009 Aug 10;188(3):223-9 20540040 - J Nephrol. 2010 Nov-Dec;23(6):683-92 11522872 - Nephrol Dial Transplant. 2001 Sep;16(9):1870-8 17035945 - Kidney Int. 2007 Feb;71(3):252-9 15126650 - Nephrol Dial Transplant. 2004 Mar;19 Suppl 1:i19-24 2910921 - J Clin Invest. 1989 Jan;83(1):66-73 8014116 - J Anat. 1994 Apr;184 ( Pt 2):227-37 15663754 - Semin Dial. 2005 Jan-Feb;18(1):8-12 Nagano N (CIT0019) 2001; 16 Behets GJ (CIT0021) 2009; 20 Xu J (CIT0025) 1994; 184 Finn WF (CIT0005) 2005; 18 CIT0011 Damment SJ (CIT0023) 2007; 171 Behets GJ (CIT0016) 2004; 15 Lacour B (CIT0027) 2005; 67 Shigematsu T (CIT0012) 2008; 70 Sacchiero R (CIT0026) 2003; 14 Danese MD (CIT0003) 2008; 3 CIT0014 Sprague SM (CIT0015) 2009; 72 Slatopolsky EA (CIT0009) 1999; 55 Vogel H (CIT0018) 2006 CIT0001 Shinaberger CS (CIT0006) 2008; 88 Damment SJ (CIT0028) 2009; 188 Meyers FH (CIT0030) 1980 Joy MS (CIT0010) 2003; 42 Arenas MD (CIT0013) 2010; 23 CIT0002 CIT0007 CIT0029 Eknoyan G (CIT0004) 2003; 42 Kato M (CIT0024) 1989; 24 Evans CH (CIT0022) 1990 CIT0008 Nagano N (CIT0020) 2003; 18 |
References_xml | – volume: 24 start-page: 135 issue: 2 year: 1989 ident: CIT0024 publication-title: Gastroenterol Jpn. doi: 10.1007/BF02774187 contributor: fullname: Kato M – volume: 23 start-page: 683 issue: 6 year: 2010 ident: CIT0013 publication-title: J Nephrol. contributor: fullname: Arenas MD – volume: 72 start-page: 252 issue: 4 year: 2009 ident: CIT0015 publication-title: Clin Nephrol. doi: 10.5414/CNP72252 contributor: fullname: Sprague SM – volume: 14 start-page: 205A year: 2003 ident: CIT0026 publication-title: J Am Soc Nephrol. doi: 10.1097/01.ASN.0000070076.01798.0D contributor: fullname: Sacchiero R – ident: CIT0014 doi: 10.1002/jps.20956 – volume: 88 start-page: 1511 issue: 6 year: 2008 ident: CIT0006 publication-title: Am J Clin Nutr. doi: 10.3945/ajcn.2008.26665 contributor: fullname: Shinaberger CS – volume: 15 start-page: 2219 issue: 8 year: 2004 ident: CIT0016 publication-title: J Am Soc Nephrol. doi: 10.1097/01.ASN.0000133022.32912.95 contributor: fullname: Behets GJ – volume: 42 start-page: 1 issue: 4 year: 2003 ident: CIT0004 publication-title: Am J Kidney Dis. doi: 10.1016/S0272-6386(03)00905-3 contributor: fullname: Eknoyan G – volume: 42 start-page: 96 issue: 1 year: 2003 ident: CIT0010 publication-title: Am J Kidney Dis. doi: 10.1016/S0272-6386(03)00554-7 contributor: fullname: Joy MS – volume: 3 start-page: 1423 issue: 5 year: 2008 ident: CIT0003 publication-title: Clin J Am Soc Nephrol. doi: 10.2215/CJN.01060308 contributor: fullname: Danese MD – ident: CIT0002 doi: 10.1111/j.1523-1755.2005.00185.x – volume: 18 start-page: 2014 issue: 10 year: 2003 ident: CIT0020 publication-title: Nephrol Dial Transplant. doi: 10.1093/ndt/gfg309 contributor: fullname: Nagano N – ident: CIT0007 doi: 10.1093/ndt/gfh1004 – start-page: 325 volume-title: Review of Medical Pharmacology year: 1980 ident: CIT0030 contributor: fullname: Meyers FH – ident: CIT0011 doi: 10.1185/030079907X242719 – volume: 20 start-page: 537A year: 2009 ident: CIT0021 publication-title: J Am Soc Nephrol. contributor: fullname: Behets GJ – ident: CIT0029 doi: 10.1038/sj.ki.5001932 – volume-title: Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays year: 2006 ident: CIT0018 doi: 10.1007/3-540-29804-5 contributor: fullname: Vogel H – ident: CIT0001 doi: 10.1097/01.ASN.0000133041.27682.A2 – volume: 67 start-page: 1062 issue: 3 year: 2005 ident: CIT0027 publication-title: Kidney Int. doi: 10.1111/j.1523-1755.2005.00171.x contributor: fullname: Lacour B – volume: 18 start-page: 8 issue: 1 year: 2005 ident: CIT0005 publication-title: Semin Dial. doi: 10.1111/j.1525-139X.2005.18116.x contributor: fullname: Finn WF – volume: 16 start-page: 1870 issue: 9 year: 2001 ident: CIT0019 publication-title: Nephrol Dial Transplant. doi: 10.1093/ndt/16.9.1870 contributor: fullname: Nagano N – volume-title: Biochemistry of the Lanthanides year: 1990 ident: CIT0022 doi: 10.1007/978-1-4684-8748-0 contributor: fullname: Evans CH – volume: 70 start-page: 404 issue: 5 year: 2008 ident: CIT0012 publication-title: Clin Nephrol. doi: 10.5414/CNP70404 contributor: fullname: Shigematsu T – volume: 171 start-page: 69 year: 2007 ident: CIT0023 publication-title: Toxicol Lett. doi: 10.1016/j.toxlet.2007.04.005 contributor: fullname: Damment SJ – volume: 188 start-page: 223 issue: 3 year: 2009 ident: CIT0028 publication-title: Toxicol Lett. doi: 10.1016/j.toxlet.2009.03.020 contributor: fullname: Damment SJ – volume: 184 start-page: 227 year: 1994 ident: CIT0025 publication-title: J Anat. contributor: fullname: Xu J – volume: 55 start-page: 299 issue: 1 year: 1999 ident: CIT0009 publication-title: Kidney Int. doi: 10.1046/j.1523-1755.1999.00240.x contributor: fullname: Slatopolsky EA – ident: CIT0008 doi: 10.1172/JCI113886 |
SSID | ssj0015872 |
Score | 2.0397542 |
Snippet | Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate... |
SourceID | pubmedcentral crossref pubmed informaworld informahealthcare |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 217 |
SubjectTerms | Aluminum Hydroxide - pharmacology Aluminum Hydroxide - therapeutic use Animals Calcium - metabolism Calcium Carbonate - pharmacology Calcium Carbonate - therapeutic use Chelating Agents - pharmacology Chelating Agents - therapeutic use chronic kidney disease Dogs Drug Evaluation, Preclinical Feces - chemistry hyperphosphatemia Hyperphosphatemia - drug therapy Hyperphosphatemia - etiology kidney diseases Kidney Failure, Chronic - complications Kidney Failure, Chronic - metabolism Lanthanum - pharmacology Lanthanum - therapeutic use lanthanum carbonate Lrnf Laboratory Study Male Mice phosphate binder Phosphates - analysis Phosphates - pharmacokinetics Phosphates - urine Phosphorus Radioisotopes - analysis Phosphorus Radioisotopes - urine Polyamines - pharmacology Polyamines - therapeutic use Rats Rats, Sprague-Dawley Sevelamer |
Title | Pharmacology of the Phosphate Binder, Lanthanum Carbonate |
URI | https://www.tandfonline.com/doi/abs/10.3109/0886022X.2011.552821 https://www.ncbi.nlm.nih.gov/pubmed/21332344 https://pubmed.ncbi.nlm.nih.gov/PMC3082170 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELVQKyEuqOxlqXLgiEXi2FmObaGqEEU9FKmcotixFQ6kVZcDf89MnJYWBEick4msZzvznpc3hFwbkWrFhUeZznzKgdNTmSmPBlEqMy59lUoUioOnoP_MH8ZivHGLH49VooY21iii_Ffj5E5lWYEEfSxvYWIEkHrG1oBTCFANoH_qDJg3jnT3pb_eRxBRWb4JIyiG2MtzP35lKzk1KuvSfH0Q64ud6UbS2j5QuZGheg2yX1FLp23HwgHZ0cUh2R1Um-dHJB5-2lS_OxPjAPdzhvlkPs2BcDodNE6c3TiPgHWeFss3p5vOJC6u62My6t2Pun1aVU6gCgjFggYGErdWrtICMpAUgeIx1y6LvYz7MjLaFYrxwEgvBEnjZixIjR8yGXpKy9D3T0itmBT6jDixjn2NtdNdGfAoBTUSC2CMoWEhcBMlm4SuEEum1h8jAV2BCCcrhBNEOLEIN0n4DdakmjbzPyKjTfCTRbmiYWz5EQz7LfTU9s-6iQykOfM5h-Zs9dz6BXTd3n5SvOal-zb6-wBs5_9vzgXZsyvTeJLtktQWs6W-AmqzkK1y9LZIvd256_Q-ADEe7xU |
link.rule.ids | 230,315,786,790,891,27533,27955,27956,59496,59497,61571,61572 |
linkProvider | Taylor & Francis |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV09T8MwELVQkYAFle_ymYERq_mwk3iEiipAW3UoUpmi2LEVBtKqTQf-Pec4DS0IkJiTi6wXO_eefXmH0LWiiRSEOtiVqYcJcHrMU-FgP0x4SrgnEq6FYn_gR8_kcUyX1YTzqqxSa2hljCLKb7Ve3Hozul1KTJu1YWX4kHvGxoGTUpANIIA2KSNM6y_7JaoPEmhY9m_SEViHmL_nfnzKWnZqVt6lWV2J9cXPdCVrrVdUrqSobhPtVtzSujWTYQ9tyHwfbfWr0_MDxIafPtXv1kRZQP6sYTaZTzNgnNaddk6c3Vg9ADtL8sWb1UlmXO-uy0M06t6POhGuWidgAYyiwL6CzC2FLSSFFMSpLwgj0naZkxKPh0raVLjEV9wJQNPYqesnygtcHjhC8sDzjlAjn-TyBFlMMk_q5uk290mYgBxhFChjoNwAyIngLYSXiMVTY5ARg7DQCMdLhGONcGwQbqHgG6xxtW7mf0SGq-DHRbmloUz_ER32W-ixeT_1EF3Q5q5HCAxn7c3VN2jb7fUr-WtW2m9rgx-A7fT_w7lC29Go34t7D4OnM7Rjtql1Wds5ahSzhbwAnlPwy3ImfwC8OfEZ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV27TsMwFLUQSBULKu_yzMCI1TzsJB6hUBVoqw5FKlMUO7bCQFq16cDfcx2nIQUBEnNyI-vYzj3Hj3MRulI0loJQB7sy8TABTo95IhzshzFPCPdEzLVQHAz93jN5nNBJ7Ra_PlapNbQyRhHFv1pP7lmi2oXCtFkbJoYPqWdiDDgpBdUA-meLMsL0GLdfetU-Ag2L8k06AusQc3nux6-sJadmaV2aVgexvtiZ1pLW-oHKWobqNtFOSS2tGzMWdtGGzPZQY1Bunu8jNvq0qX63psoC7meN0ulilgLhtG61ceL82uoD1mmcLd-sTjznenFdHqBx937c6eGycgIWQChy7CtI3FLYQlLIQJz6gjAibZc5CfF4qKRNhUt8xZ0AJI2duH6svMDlgSMkDzzvEG1m00weI4tJ5kldO93mPgljUCOMAmMMlBsANxG8hfAKsWhm_DEi0BUa4WiFcKQRjgzCLRR8gzUqp83ij8iwDn6UFysaypQf0WG_hR6Z_qma6II0dz1CoDlrPVe9oF23159kr2nhvq39fQC2k_835xI1RnfdqP8wfDpF22aRWh9qO0Ob-Xwpz4Hl5PyiGMgfPxvwQg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacology+of+the+Phosphate+Binder%2C+Lanthanum+Carbonate&rft.jtitle=Renal+failure&rft.au=Damment%2C+Stephen+J.P.&rft.date=2011-03-01&rft.pub=Taylor+%26+Francis&rft.issn=0886-022X&rft.eissn=1525-6049&rft.volume=33&rft.issue=2&rft.spage=217&rft.epage=224&rft_id=info:doi/10.3109%2F0886022X.2011.552821&rft.externalDBID=0YH&rft.externalDocID=552821 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0886-022X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0886-022X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0886-022X&client=summon |